← Human Trials & Peer-Reviewed Studies
A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly
Plain-language guide to PMID 10474124 (1999): crossover controlled clinical trial study of Octreotide and Somatostatin in 7 patients.
Key Facts
- PMID
- 10474124
- Journal
- European journal of endocrinology
- Year
- 1999
- Study type
- Controlled Clinical Trial
- Authors
- Cozzi R et al. (5 authors)
- DOI
- 10.1530/eje.0.1410267
What This Study Did, in Plain Language
What Was Tested
Researchers studied Octreotide and Somatostatin in this controlled clinical trial publication.
The recent availability of octreotide (OC)-LAR, a somatostatin analog to be administered at 28-day intervals, has prompted them to compare, in the same group of patients, its effects and those of another somatostatin analog already available, lanreotide-SR (LSR, to be administered at 14-day intervals).
Why It Was Studied
At present long-acting somatostatin analogs represent the first-line medical treatment of acromegaly.
Who Took Part
The abstract describes 7 patients taking part.
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
Twelve somatostatin analog-sensitive acromegalic patients with active disease were enrolled in a prospective open sequential study after giving their informed consent.
After chronic treatment with LSR (6-24 months), the patients were changed to treatment with OC-LAR, without wash-out.
How the Study Was Run
The design is described as crossover.
In the crossover set-up each of the patients took both Octreotide and the comparison in turn, acting as their own control.
GH (mean of three, hourly samples) and IGF-I concentrations were evaluated on the same day as each administration of the drug, before its injection.
What Was Measured
Topics PubMed links to this paper include Acromegaly, Anti-Inflammatory Agents, Non-Steroidal, Blood Glucose, Gallbladder, Glycated Hemoglobin, Hormones and Human Growth Hormone.
What This Means in Plain Language
The paper is a crossover study of Octreotide and Somatostatin in 7 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1999 (European journal of endocrinology), a journal based in England.
More context: the Octreotide compound page and the Somatostatin compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.